Newborn Screening Programs for Sickle Cell Disease

The Case for Newborn Screening

Newborn screening (NBS) for sickle cell disease is one of the most cost-effective public health interventions available. The evidence is unequivocal: early identification of infants with SCD followed by initiation of prophylactic penicillin, pneumococcal vaccination, and parental education reduces under-5 mortality by 70% or more. In the United States, universal newborn screening for SCD has been standard since the 1980s, and childhood mortality from the disease has dropped to less than 1%.

In sub-Saharan Africa, where the vast majority of SCD births occur, newborn screening programs remain limited in scope and coverage. Most children with SCD are diagnosed only when they present with a complication — often a severe infection, splenic sequestration crisis, or severe anemia — by which time irreversible damage may have occurred.

Screening Methods

Several laboratory methods are used for hemoglobin identification in newborn screening:

• High-Performance Liquid Chromatography (HPLC): Considered the gold standard for hemoglobin analysis. HPLC separates and quantifies hemoglobin variants with high precision. Equipment costs $30,000 to $80,000, requiring stable electricity and trained technicians, making it most suitable for centralized reference laboratories.
• Isoelectric Focusing (IEF): A gel-based electrophoresis technique that offers excellent sensitivity and specificity. Less automated than HPLC but has lower capital costs.
• Point-of-Care (POC) Rapid Tests: Newer technologies like Sickle SCAN and HemoTypeSC provide results in 5 to 20 minutes from a finger-prick blood sample. Transformative for settings where centralized laboratory access is limited.
• Capillary Electrophoresis: An increasingly popular alternative to HPLC with potentially lower consumable costs.

Program Design Considerations

Designing a successful NBS program for SCD in Africa requires careful attention to sample collection strategy (dried blood spot cards collected within 24 to 72 hours of birth), laboratory network design (hub-and-spoke models balancing centralization with turnaround time), results communication (digital platforms for automated result notification), follow-up and enrollment (guaranteeing every identified child is enrolled in comprehensive care), and quality assurance (external quality assessment and proficiency testing).

The follow-up component is critical. Screening without assured follow-up is unethical and ineffective. Programs must guarantee that every child identified with SCD is enrolled in comprehensive care, initiated on penicillin prophylaxis, and connected to a healthcare provider. This is where patient tracking systems become essential.

Nigeria's Screening Landscape

Nigeria, with the world's highest SCD birth prevalence, currently lacks a national universal newborn screening program. Notable pilot programs include the Sickle Cell Foundation Nigeria's initiatives in Lagos and Ogun states, academic hospital-based programs at UCH Ibadan and ABUTH Zaria, and various NGO-supported programs. These have collectively screened hundreds of thousands of newborns but represent a small fraction of Nigeria's approximately 7 million annual births.

The primary barriers remain funding, laboratory infrastructure, workforce capacity, and the absence of digital systems to track screened infants from identification through enrollment into care — precisely the gap that Tracka is designed to fill.

International Clinical Recommendations

International health bodies recommend that all countries with significant SCD prevalence implement newborn screening programs integrated into existing maternal and child health platforms. Key recommendations include screening all newborns in high-prevalence areas, using validated laboratory methods with quality assurance, ensuring positive infants are enrolled in care within 3 months, and building digital tracking systems to monitor the screening-to-care cascade.

Tracka's Role in Newborn Screening

Tracka supports the entire NBS cascade by digitizing sample tracking from collection through laboratory processing, automating result notification to healthcare workers, triggering enrollment workflows when a positive result is confirmed, tracking follow-up visit completion and prophylactic therapy initiation, and generating program-level metrics including screening coverage rates, positivity rates, time to diagnosis, and loss-to-follow-up rates. This end-to-end digital infrastructure ensures that the promise of newborn screening — early identification leading to early intervention — is fully realized for every affected child.